NASDAQ · THTX
Healthcare · Drug Manufacturers - Specialty & Generic
$3.39
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 11:39 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
THTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning THTX.
THTX research
Company profile and research snapshot.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 3, 2025 | RESEARCH CAPITAL CORPORATION | Buy | — |
| Jul 2, 2025 | RESEARCH CAPITAL CORPORATION | Buy | — |
| Apr 14, 2025 | LEEDE JONES GABLE | Buy | — |
| Apr 13, 2025 | LEEDE JONES GABLE | Buy | — |
| Mar 26, 2025 | RESEARCH CAPITAL CORPORATION | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 25, 2025
Theratechnologies Inc. has completed an acquisition by Future Pak, with shareholders receiving $3.01 per share in cash and a contingent value right (CVR) with potential additional payments of up to $1.19 per share if certain milestones are achieved.
Benzinga · Sep 16, 2025
Theratechnologies Inc. has received final court approval for a plan of arrangement to be acquired by Future Pak, with the transaction expected to close around September 25, 2025.
Benzinga · Sep 12, 2025
Theratechnologies shareholders voted 97.44% in favor of a proposed arrangement to be acquired by Future Pak, with the final court order expected on September 16, 2025.
seekingalpha.com · Sep 12, 2025
Theratechnologies Inc. (TSX:TH:CA ) Special Meeting of Shareholders of Theratechnologies Call Company Participants Frank Holler - Chair of the Board Philippe Dubuc - Senior VP & CFO Presentation Operator Hello, and welcome to the Special Meeting of Shareholders of Theratechnologies. Please note that today's meeting is being recorded.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning THTX.
No results
No recent SID articles mention THTX.
